Literature DB >> 20614193

The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).

Mark B Faries1, John F Thompson, Alistair Cochran, Robert Elashoff, Edwin C Glass, Nicola Mozzillo, Omgo E Nieweg, Daniel F Roses, Harold J Hoekstra, Constantine P Karakousis, Douglas S Reintgen, Brendon J Coventry, He-Jing Wang, Donald L Morton.   

Abstract

BACKGROUND: Complete lymph node dissection, the current standard treatment for nodal metastasis in melanoma, carries the risk of significant morbidity. Clinically apparent nodal tumor is likely to impact both preoperative lymphatic function and extent of soft tissue dissection required to clear the basin. We hypothesized that early dissection would be associated with less morbidity than delayed dissection at the time of clinical recurrence.
MATERIALS AND METHODS: The Multicenter Selective Lymphadenectomy Trial I randomized patients to wide excision of a primary melanoma with or without sentinel lymph node biopsy. Immediate completion lymph node dissection (early CLND) was performed when indicated in the SLN arm, while therapeutic dissection (delayed CLND) was performed at the time of clinical recurrence in the wide excision-alone arm. Acute and chronic morbidities were prospectively monitored.
RESULTS: Early CLND was performed in 225 patients, and in the wide excision-alone arm 132 have undergone delayed CLND. The 2 groups were similar for primary tumor features, body mass index, basin location, and demographics except age, which were higher for delayed CLND. The number of nodes evaluated and the number of positive nodes was greater for delayed CLND. There was no significant difference in acute morbidity, but lymphedema was significantly higher in the delayed CLND group (20.4% vs. 12.4%, P = .04). Length of inpatient hospitalization was also longer for delayed CLND.
CONCLUSION: Immediate nodal treatment provides critical prognostic information and a likely therapeutic effect for those patients with nodal involvement. These data show that early CLND is also less likely to result in lymphedema.

Entities:  

Mesh:

Year:  2010        PMID: 20614193      PMCID: PMC2970739          DOI: 10.1245/s10434-010-1203-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Feasibility of a novel approach to inguinal lymphadenectomy: minimally invasive groin dissection for melanoma.

Authors:  Keith A Delman; David A Kooby; Kenneth Ogan; Wayland Hsiao; Viraj Master
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

2.  Identifying risk factors for complications following sentinel lymph node biopsy for melanoma.

Authors:  J Brent Roaten; Nate Pearlman; Ricardo Gonzalez; Rene Gonzalez; Martin D McCarter
Journal:  Arch Surg       Date:  2005-01

3.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

4.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

5.  Positive iliac and obturator nodes in melanoma: survival and prognostic factors.

Authors:  L J Strobbe; A Jonk; A A Hart; O E Nieweg; B B Kroon
Journal:  Ann Surg Oncol       Date:  1999 Apr-May       Impact factor: 5.344

6.  Surgical procedures and lymphedema of the upper and lower extremity.

Authors:  Constantine P Karakousis
Journal:  J Surg Oncol       Date:  2006-02-01       Impact factor: 3.454

7.  Complications associated with sentinel lymph node biopsy for melanoma.

Authors:  William R Wrightson; Sandra L Wong; Michael J Edwards; Celia Chao; Douglas S Reintgen; Merrick I Ross; R Dirk Noyes; Vicki Viar; Patricia B Cerrito; Kelly M McMasters
Journal:  Ann Surg Oncol       Date:  2003-07       Impact factor: 5.344

8.  Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma.

Authors:  Gary Lawton; Hope Rasque; Stephan Ariyan
Journal:  J Am Coll Surg       Date:  2002-09       Impact factor: 6.113

9.  Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection.

Authors:  P Beitsch; C Balch
Journal:  Am J Surg       Date:  1992-11       Impact factor: 2.565

10.  Morbidity following prophylactic and therapeutic lymph node dissection for melanoma--a comparison.

Authors:  C Ingvar; C Erichsen; P E Jönsson
Journal:  Tumori       Date:  1984-12-31
View more
  36 in total

Review 1.  Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Authors:  Donald L Morton
Journal:  Clin Exp Metastasis       Date:  2012-06-24       Impact factor: 5.150

2.  Surgery: Limitations of prospective surgical oncology trials - a US view.

Authors:  Charles M Balch; Heidi Nelson; John E Niederhuber
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

3.  Completing the Dissection in Melanoma: Increasing Decision Precision.

Authors:  Mark B Faries
Journal:  Ann Surg Oncol       Date:  2018-01-04       Impact factor: 5.344

4.  MSLT-I-response of clinical trial investigators.

Authors:  Mark B Faries; Alistair J Cochran; John F Thompson
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

5.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

Review 6.  Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Authors:  Athanassios Kyrgidis; Thrasivoulos Tzellos; Simone Mocellin; Zoe Apalla; Aimilios Lallas; Pierluigi Pilati; Alexander Stratigos
Journal:  Cochrane Database Syst Rev       Date:  2015-05-16

Review 7.  Surgical treatment of melanoma patients with early sentinel node involvement.

Authors:  Rosemarie E Hardin; Julie R Lange
Journal:  Curr Treat Options Oncol       Date:  2012-09

8.  Melanoma: MSLT-1--putting sentinel lymph node biopsy into context.

Authors:  Vernon K Sondak; Jonathan S Zager
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

9.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

10.  Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.

Authors:  Georgia M Beasley; Paul Speicher; Ketan Sharma; Hilliard Seigler; April Salama; Paul Mosca; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2013-12-24       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.